What Is Evolus, Inc. Common Stock (EOLS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Evolus, Inc. Common Stock at its current price of $5.96. The composite intrinsic value is estimated at $4.49 (-24.6% average return), with 7 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +59.4% (fair value: $9.50), while Bayesian DCF is the most conservative at -85.6% ($0.86). The spread between these extremes — +145.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About EOLS?
10 of 13 models are currently active for EOLS. Of these, 3 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates EOLS's intrinsic value at $0.86, implying -85.6% downside from the current price. See which stocks rank higher →
How Does EOLS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, EOLS ranks #124 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Evolus, Inc. Common Stock competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is EOLS a Value Trap?
CirclFi's Value Trap algorithm assigns EOLS a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Evolus, Inc. Common Stock. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Evolus, Inc. Common Stock is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +145.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every EOLS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across EOLS's 10 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad